Pfizer, Moderna and Valneva all have mRNA gene therapy shots in their vaccine pipelines, with Moderna announcing they have two candidates they’re working on.
Pfizer and Valneva, which reported problems with keeping trial participants in their late-stage clinical trials, said they are still planning to apply for FDA approval sometime in 2025.
“Aside from the vaccine, researchers are looking into other alternatives to protect against Lyme disease, including a human monoclonal antibody as pre-exposure prophylaxis for Lyme disease and more sensitive tests that look at biomarkers the body releases when it has Lyme disease, as well as vaccinating mice in tick-infested areas with the hopes of spreading the immunity to the ticks themselves,” the New York Post reported.
SOURCE:
Source: Original Article
Publish Date: 2023-04-26 18:08:14